Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="BENARD, J" or (type exact bookEditor and editor="BENARD, J")

Add to list
- Journal Article
- A1
- open access
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)

G Schleiermacher, J Michon, A Ribeiro, G Pierron, V Mosseri, H Rubie, C Munzer, J Bénard, N Auger, V Combaret, et al.

(2011) BRITISH JOURNAL OF CANCER. 105(12). p.1940-1948
Add to list
- Conference Paper
- C3
Risk estimation of neuroblastoma patients by gene expression based classification

M Fischer, A Oberthuer, B Brors, F Westermann, J Theissen, S Asgharzadeh, R Seeger, P Scaruffi, GP Tonini, I Janoueix-Lerosey, et al.

(2009) PEDIATRIC BLOOD & CANCER. 53(5). p.741-741
Add to list
- Journal Article
- A1
Quality assessment of genetic markers used for therapy stratification

IM AMBROS, J BENARD, M BOAVIDA, N BOWN, H CARON, V COMBARET, J COUTURIER, C DARNFORS, O DELATTRE, J FREEMAN-EDWARD, et al.

(2003) JOURNAL OF CLINICAL ONCOLOGY. 21(11). p.2077-2084
Add to list
- Journal Article
- A1
Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11Q deletion in tumors lacking MYCN amplification.

D PLANTAZ, Jo Vandesompele (UGent) , Nadine Van Roy (UGent) , M LASTOWSKA, N BOWN, V COMBARET, MC FAVROT, O DELATTRE, J MICHON, J BENARD, et al.

(2001) INTERNATIONAL JOURNAL OF CANCER. 91(5). p.680-686
Add to list
- Journal Article
- A2
Deletion of chromosome 11q is the most frequent deletion detected by CGH in metastatic neuroblastoma lacking MYCN amplification

D PLANTAZ, J VANDESOMPELE, Nadine Van Roy (UGent) , N BROWN, J NICHOLSON, M LASTOWSKA, A PEARSON, C BRINKSCHMIDT, H CHRISTIANSEN, F LAMPERT, et al.

(2001) Int. J. of Cancer. 91. p.680-686

Academic Bibliography

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)

Risk estimation of neuroblastoma patients by gene expression based classification

Quality assessment of genetic markers used for therapy stratification

Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11Q deletion in tumors lacking MYCN amplification.

Deletion of chromosome 11q is the most frequent deletion detected by CGH in metastatic neuroblastoma lacking MYCN amplification

Contents

Support

Contact